NORD is very grateful to David W. Carley, PhD, Professor of Biobehavioral Health Sciences, Medicine and Bioengineering; Director, Center for Narcolepsy, Sleep and Health Research (CNSHR), University of Illinois at Chicago, for assistance in the preparation of this report.
Synonyms of Narcolepsy
- Gelineau's syndrome
- narcoleptic syndrome
- paroxysmal sleep
- narcolepsy with cataplexy
- narcolepsy without cataplexy
Narcolepsy is a neurological sleep disorder characterized by chronic, excessive attacks of drowsiness during the day, sometimes called excessive daytime sleepiness (EDS). Attacks of drowsiness may persist for only a few seconds or several minutes. These episodes vary in frequency from a few incidents to several during a single day. Nighttime (nocturnal) sleep patterns may also be disrupted. Three additional symptoms often associated with narcolepsy are sudden extreme muscle weakness (cataplexy), a specific type of hallucination that occurs just before falling asleep or upon awakening, and brief episodes of paralysis while waking up. Narcolepsy also may be associated with "automatic behavior", i.e. doing something automatically without any memory afterward. The incidence of narcolepsy is approximately 1 in 2,000 and most researchers believe that the disorder remains undiagnosed or misdiagnosed in many cases.
There is increasing evidence that narcolepsy is an autoimmune disorder. Autoimmune disorders are caused when the body's immune system mistakenly attacks healthy tissue or cells. In narcolepsy, the immune system destroys certain brain cells that produce a peptide called hypocretin. Hypocretin impacts on many brain functions, but the details of its actions are not yet understood. Why the immune system attacks healthy cells in narcolepsy is unknown and additional environmental and genetic factors may play a role in the development of the disorder.
The development and severity of symptoms associated with narcolepsy vary greatly from one person to another. The onset of symptoms initially occurs one at a time; appearance of new symptoms may be separated by years, with sleepiness generally preceding cataplexy. Narcolepsy usually begins in an adolescent whose initial symptoms are mild but worsen with age. Sometimes symptoms do not change for months, while at other times symptoms may change very quickly. Depending upon the severity of the disorder, narcolepsy can dramatically affect a person's daily routine, disrupting all aspects of a person's life.
Excessive daytime sleepiness (EDS) is usually the first symptom of narcolepsy. People with narcolepsy typically experience periods of drowsiness, tiredness, lack of energy, an irresistible urge to sleep ("sleep attack"), and/or an inability to resist sleep. This susceptibility to unending drowsiness and/or falling asleep may occur every day but the severity varies from day to day and throughout each day. These episodes are more likely to occur during monotonous, boring activities such as watching television. However, the episodes can occur at any time even when a person is walking, talking, eating or driving a car. Consequently, narcolepsy can profoundly disrupt a person's life. Affected individuals may fall asleep for brief periods ranging from a few seconds to several minutes. A characteristic finding of narcolepsy is that affected individuals often feel dramatically more awake and alert following short naps.
Narcolepsy can also disrupt nighttime sleeping patterns. Affected individuals may frequently awaken during the night and may be wide awake for significant periods during the night. Despite disrupted sleep patterns, the total sleep time for people with narcolepsy in every 24 hour period is generally normal because they sleep repeatedly for short periods during the day and night.
Many individuals with narcolepsy experience weakness and the sudden loss of voluntary muscle tone (cataplexy). This often occurs during times of intense emotions such as laughter, anger, elation, and/or surprise. Episodes of cataplexy may occur as short periods of partial muscle weakness and can vary in duration and severity. In some cases, a cataplectic attack may be barely noticeable. Affected individuals may experience very brief, mild episodes that may cause the knees to buckle, the jaws to sage, the eyelids to droop or the head to drop. Occasionally in severe cases, there may be an almost complete loss of muscle control that lasts for several minutes. During a severe cataplectic attack, speech and movement may become difficult or impossible although there is no loss of consciousness. Cataplexy may improve as affected individuals grow older.
Some people with narcolepsy do not have cataplexy, and cataplexy is not necessary for a diagnosis of narcolepsy. Cataplexy usually develops approximately several weeks to months after the development of excessive daytime sleepiness. In rare cases, cataplexy may precede the development of difficulties in maintaining alertness.
Some individuals with narcolepsy may experience hallucinations that may occur at the beginning or at the end of a sleep period. These are often vivid and frightening. Examples of hallucinations may include hearing a phone ring or a person walking nearby, seeing people or animals that aren't there, or having an out of body experience. When the hallucinations occur upon awakening, they are called hypnopompic hallucinations; when they occur when falling asleep, they are called hypnagogic hallucinations. Hallucinations often occur in conjunction with sleep paralysis.
People with narcolepsy may experience temporary "sleep paralysis". They may be briefly unable to move their limbs or heads or speak. Episodes of sleep paralysis are very short and typically coincide with falling asleep or waking up. Affected individuals regain all movements after these brief episodes.
Some affected individuals may also experience additional symptoms including fatigue, depression, difficulty concentrating, and memory problems. Periodic leg movements and sleep apnea have also been reported in individuals with narcolepsy.
Narcolepsy with cataplexy has been linked to low levels of a specific brain chemical called hypocretin (also known as orexin). This chemical plays an important role in regulating sleep and other functions. Hypocretin also functions as a neurotransmitter, a chemical that modifies, amplifies or transmits nerve impulses from one nerve cell (neuron) to another, enabling nerve cells to communicate. Researchers have determined that the number of neurons that produce hypocretin is significantly reduced in individuals with narcolepsy. Hypocretin-producing neurons are found in the hypothalamus, the area of the brain that regulates many functions including sleep, appetite and body temperature. In some individuals as many as 80-90 percent of hypocretin-producing neurons in the hypothalamus are lost. Individuals who have narcolepsy with cataplexy have the lowest levels of hypocretin.
In 2009, researchers discovered that individuals with narcolepsy have changes in a gene known as a T cell receptor gene. (T cells are specialized immune cells that play a role in all immune system responses). This variant T cell receptor gives individuals a genetic predisposition to developing narcolepsy. A genetic predisposition means that a person carries a gene or genes for a disease, but that it may not be expressed unless other additional factors are present. The genetic factors associated with narcolepsy are insufficient to cause the disorder by themselves.
Many cases of narcolepsy are strongly associated with a group of genes known as the human leukocyte antigen (HLA) complex located on human chromosome 6. These genes play a role in regulating the proper function of the immune system. Affected individuals often have variants of some of these genes. The exact role and significance of these HLAs in narcolepsy are not fully understood. Most disorders associated with the HLA complex have an immunological component to the disorder, either through autoimmunity or because of an improper immune system response to a foreign substance. Researchers believe that HLA and the variant T cell found in individuals with narcolepsy interact in a manner that causes the destruction of brain cells that produce hypocretin.
The exact cause of narcolepsy without cataplexy is unknown.
The exact number of people with narcolepsy in the United States is unknown. One estimate places the prevalence at .03 percent to .16 percent of the general population in various ethnic groups worldwide. One U.S. study placed the incidence of new cases of narcolepsy at .74 per 100,000 person-years in the general population in the United States. The disorder has also been estimated to affect 1 in 2,000 people in the general population. However, because narcolepsy often goes unrecognized or misdiagnosed, determining its true frequency in the general population is difficult.
The onset of narcolepsy can occur anytime between early childhood and 50 years of age. Two peak time periods have been identified; one around 15 years of age and another around 36 years of age. Some researchers believe that narcolepsy is under-diagnosed in children. Narcolepsy tends to remain a lifelong condition. Although the nature and severity of symptoms experienced by an affected person may varying over time, the disorder is not progressive.
Narcolepsy was first described in the medical literature in 1880 by Gelineau and in 1887 by Westphal.
Symptoms of the following disorders can be similar to those of narcolepsy. Comparisons may be useful for a differential diagnosis:
Idiopathic hypersomnia is a rare condition characterized by episodes or extreme sleepiness that occur for no identifiable reason (idiopathic). Episodes may be chronic or constant. The disorder differs from narcolepsy in that affected individuals do not experience sudden sleep episodes or develop cataplexy. In addition, affected individuals do not feel refreshed after a nap. Some individuals with idiopathic hypersomnia sleep for long periods (e.g., more than 10 hours); others sleep for shorter periods (e.g., fewer than 10 hours). Idiopathic hypersomnia can disrupt many aspects of life. Behavioral modification and certain medications are used to treat the disorder.
Sleep apnea is a common sleep disorder characterized by temporary, recurrent interruptions of breathing during sleep. Symptoms of the disorder include frequent interruptions of sleep during the night, excessive sleepiness during the day, loud snoring, irritability, poor concentration and/or cognition. Obesity, including neck obesity and narrow airways in the neck are commonly associated with sleep apnea. In obstructive sleep apnea syndrome, the most common form of sleep apnea, labored breathing is interrupted by airway collapse. Partial awakening may then occur and the person may gasp for air. Sleep is resumed as breathing begins again. Untreated sleep apnea may be associated with high blood pressure, irregular heart beats, and increased risks for heart attack, heart failure, stroke and diabetes. (For more information on this disorder, choose "sleep apnea" as your search term in the Rare Disease Database.)
Kleine-Levin syndrome is a rare disorder characterized by the need for excessive amounts of sleep (hypersomnolence), (i.e., up to 20 hours a day); excessive food intake (compulsive hyperphagia); and behavioral changes such as an abnormally uninhibited sexual drive. When awake, affected individuals may exhibit irritability, lack of energy (lethargy), and/or lack of emotions (apathy). They may also appear confused (disoriented) and experience hallucinations. Symptoms of Kleine-Levin syndrome are cyclical. An affected individual may go for weeks or months without experiencing symptoms. When present, symptoms may persist for days to weeks. In some cases, the symptoms associated with Kleine-Levin syndrome eventually disappear with advancing age. However, episodes may recur later during life. The exact cause of Kleine-Levin syndrome is not known. (For more information, choose "Kleine-Levin" as your search term in the Rare Disease Database.)
Symptoms resembling those of narcolepsy may also occur after brain tumors (intracranial), head trauma, hardening of the arteries in the brain (cerebral arteriosclerosis), psychosis, and/or excessive amounts of protein in the blood due to kidney failure (uremia). Hypothyroidism, delayed sleep phase syndrome, periodic limb movement disorder, depression, hypoglycemia and other conditions can also cause excessive daytime sleepiness.
Narcolepsy is diagnosed based upon a thorough clinical evaluation; a careful patient and family history; objective verification of characteristic symptoms (i.e., excessive daytime drowsiness, potentially in association with cataplexy, hypnagogic hallucinations, and/or sleep paralysis); and specialized sleep studies.
Two main tests used to diagnose narcolepsy are an overnight polysomnogram (PSG) followed by a multiple sleep latency test (MSLT). A PSG is a test done during sleep and continually measures a variety of things including brain wave changes, heart rate, eye movements, limb movements, muscle tone and respiration. A PSG is usually followed by a MSLT, which measures how quickly someone falls asleep for a nap every two hours during the day (4 or 5 nap opportunities). Individuals with narcolepsy fall asleep during the day more easily than people without narcolepsy. In addition, they will enter dreaming sleep (rapid eye movement sleep) even during a brief nap; something a healthy well-slept individual will not do.
Individuals with narcolepsy often have extremely low levels of hypocretin in their cerebrospinal fluid. Testing cerebrospinal fluid for hypocretin levels may be able to assist in a diagnosis of narcolepsy.
The treatment of narcolepsy is directed toward the specific symptoms that are present in each individual. Various medications may help to alleviate certain symptoms associated with narcolepsy.
For individuals who experience excessive daytime sleepiness and sleep attacks, therapy may include administration of certain stimulants, such as modafinil (Provigil). Modafinil was approved by the Food and Drug and Administration (FDA) for the treatment of excessive daytime sleepiness in narcolepsy in 1999. Modafinil is now the most widely prescribed drug for excessive daytime sleepiness. The drug's mechanism of action appears to differ from that of other stimulants and does not appear to affect alertness or memory. In addition, evidence suggests that modafinil therapy is not associated with dependency or symptoms of withdrawal and therefore may be an effective alternative to other treatments for excessive daytime sleepiness. Modafinil is generally associated with fewer side effects than previous drugs used to treat this condition.
Previous drugs that have been used to treat excessive daytime sleepiness in narcolepsy include methylphenidate (Ritalin, Methylin), methamphetamine, or dextroamphetamine. These drugs stimulate the central nervous system and are still used when modafinil is unsuccessful. Because such medications may be associated with certain side effects, including nervousness, insomnia, or irritability, careful monitoring by physicians is required to ensure appropriate dosage adjustments and effectiveness of such therapy. In addition, close monitoring and long-term follow-up by physicians may be required if therapy is withdrawn.
Additional stimulants that have been used to treat excessive daytime sleepiness and narcolepsy include manzindol, selegiline, and pemoline.
A variety of drugs have been used to treat cataplexy. The orphan drug sodium oxybate (Xyrem) has been approved by the FDA to treat cataplexy, the sudden loss of muscular control and weakness that is associated with narcolepsy. Xyrem is also known as gamma hydroxybutyrate (GHB).
Xyrem has also been effective in improving nighttime sleep in individuals with narcolepsy. Some individuals with narcolepsy treated with high doses of the drug showed improved of daytime sleepiness. However, Xyrem is potentially associated with serious side effects. The drug is manufactured by:
3180 Porter Drive
Palo Alto, CA 94304
Individuals with cataplexy, sleep paralysis and/or hypnagogic hallucinations may be treated with certain antidepressants. Specifically, doctors often prescribe selective serotonin reuptake inhibitors, which suppress rapid eye movement sleep, to help alleviate these symptoms. These drugs include for example, fluoxetine (Prozac, Serafem, others), sertraline (Zoloft), atomoxetine (Strattera) and venlafaxine (Effexor). The most common side effects are decreased sexual desire and delayed orgasm. Other side effects can include digestive problems, restlessness, headache and insomnia. Older tricyclic antidepressants such as imipramine, desimipramine, protriptyline, and clomipramine may also be effective in reducing cataplexy, sleep paralysis and/or hallucinations, but many people are bothered by side effects, including dry mouth and constipation. Close monitoring by a physician is necessary for those taking antidepressant medications and is also required if such therapy is withdrawn.
In addition to drug therapy, many individuals have benefited from behavioral modification. Regular sleep habits are important for individuals with narcolepsy, including ensuring regular bedtime hours and preventing sleep interruptions. If possible, taking regular naps during the day may help to control excessive daytime sleepiness. Regular exercise is also recommended. Affected individuals should consider speaking with their physicians concerning the establishment of appropriate sleep schedules.
The discovery that hypocretin plays a role in the development of narcolepsy has opened new avenues of research. Ongoing studies are investigating the implantation of cells that produce hypocretin (cell transplantation); implantation of a gene that promotes the expression of hypocretin (gene therapy); and the direct administration of hypocretin through the nose (intranasal), through the blood (intravenously) or through an opening (cistern) in the subarachnoid space of the brain (intracisternally).
At this time, many technical difficulties exist that must be resolved before gene therapy can succeed.
Researchers are also studying the role and implications of the immune system in the development of narcolepsy. Therapies that modify the response of the immune system including steroids, intravenous immunoglobulin and plasmapheresis have all been studied. So far, results from the study of these therapies have been inconsistent and inconclusive.
Various additional medications are being studied for the treatment of narcolepsy including fluvoxamine, zimelidine, monamine oxidase inhibitors, and femoxitine. More research is necessary to determine the long-term safety and effectiveness of these various potential treatment options for individuals with narcolepsy.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Contact for additional information about narcolepsy:
David W. Carley, Ph.D.
Professor of Biobehavioral Health Sciences, Medicine and Bioengineering
Director, Center for Narcolepsy, Sleep and Health Research (CNSHR)
University of Illinois at Chicago
Suite 215, M/C 802
845 S. Damen Avenue
Chicago, IL 60612
NORD offers an online community for this rare disease. RareConnect was created by EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders) to provide a safe space where individuals and families affected by rare diseases can connect with each other, share vital experiences, and find helpful information and resources. You can view these international, rare disease communities at www.rareconnect.org.
NORD Member Organizations:
(To become a member of NORD, an organization must meet established criteria and be approved by the NORD Board of Directors. If you're interested in becoming a member, please contact Susan Olivo, Membership Manager, at firstname.lastname@example.org.)
Goswami M. Narcolepsy. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:561-2.
Fauci AS, et al., eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill Companies, Inc.; 1998:155.
Wyngaarden JB, et al., eds. Cecil Textbook of Medicine. 19th ed. Philadelphia, PA: W.B. Saunders Company; 1992:2065-2066.
Adams RD, et al., eds. Principles of Neurology. 4th ed. New York, NY: McGraw-Hill Companies, Inc.; 1989:314-317.
Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41:708-711.
Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat. 2008;4:557-566.
Alaez C, Lin L, Flore A-H, et al. Association of narcolepsy-cataplexy with HLA-DRB1 and DQB1 in Mexican patients: a relationship between HLA and gender is suggested. BMC Med Genet. 2008;9:79.
Black J, Duntley SP, Bogan RK, O'Malley MB. Recent advances in the treatment and management of excessive daytime sleepiness. CNS Spectr. 2007;12:1-14.
Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499-511.
Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1712-1727.
Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8:373-399.
Longstreth Jr. WT, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30:13-26.
Dauvilliers Y, Carlander B, Billiard M. Narcolepsy, from Westphal to hypocretin. Presse Med. 2004;33:1593-600.
Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56:905-8.
Mignot E. Sleep, sleep disorders and hypocretin (orexin). Sleep Med. 2004;5:S2-8.
McKenna L, McNicholas F, Childhood onset narcolepsy. A case report. Eur Child Adolesc Psychiatry. 2003;12:43-7.
Hood Bm, Harbord MG, Paediatric narcolepsy: complexities of diagnosis. J Paediatr Child Health. 2002;38:618-21.
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54:1166-1175.
Lin L, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365-376. [See comment in Cell. 1999;98:409-412.]
Bozorg AM, Benbadis SR. Narcolepsy. Emedicine Journal. http://emedicine.medscape.com/article/1188433-overview. Updated: February 19, 2010. Accessed February 8, 2012.
National Institute of Neurological Disorders and Stoke. Narcolepsy Fact Sheet. http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm. Updated December 28, 2011. Accessed February 8, 2012.
Mayo Clinic for Medical Education and Research. Narcolepsy. http://www.mayoclinic.com/health/narcolepsy/DS00345. Updated August 2, 2011. Accessed February 8, 2012.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
Copyright ©1986, 1988, 1990, 1993, 1994, 1996, 1997, 1998, 1999, 2000, 2002, 2003, 2005, 2009, 2010, 2012
Report last updated: 2012/03/02 00:00:00 GMT+0
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.